Claims

1. A pharmaceutical formulation comprising:
1 to 200 mg/mL of an antibody;
1 to 100 mM of a buffer;
0.001 to 1% of a surfactant;
(a) 10 to 500 mM of a stabilizer; or
(b) 10 to 500 mM of a stabilizer and 5 to 500 mM of a tonicity agent; or
(c) 5 to 500 mM of a tonicity agent;
at a pH in the range of from 4.0 to 7.0,
wherein the antibody is an antibody against P-selectin.

2. The formulation according to claim 1 which is a liquid formulation or a lyophilized formulation or a liquid formulation reconstituted from a lyophilized formulation.

3. The formulation according to claims 1 or2, wherein the antibody concentration is in the range of 10 mg/mL to 150 mg/ml.

4. The formulation according to any one of claims 1 to 3, wherein the stabilizer is trehalose.

5. The formulation according to any one of claims 1 to 4 wherein the surfactant is polysorbate.

6. The formulation according to any one of claims 1 to 5 wherein the buffer is a histidine-buffer.

7. The formulation according to any one of claims 1 to 6, which comprises a tonicity agent.

8. The formulation according to any one of claims 1 to 7, wherein the tonicity agent is trehalose.

9. The formulation of claim 1 which comprises:
1 to 50 mg/mL huMAb-P-selectin, 20 mM L-histidine HCl, 240 mM trehalose, 0.02% polysorbate 20, at pH 6.0;
or
1 to 50 mg/mL huMAb-P-selectin, 20 mM sodium acetate, 140 mM trehalose, 75 mM glycine, 0.04% polysorbate 20, at pH 5.2;
or
1 to 50 mg/mL huMAb-P-selectin, 20 mM L-histidine HCl, 240 mM trehalose, 0.02% polysorbate 20, at pH 6.0;
or

1 to 50 mg/mL huMAb-P-selectin, 20 mM succinate, 240 mM trehalose, 20 mM arginine, 0.02% polysorbate 20, at pH 6.0.

10. Use of a formulation according to any one of claims 1 to 20 for the preparation of a medicament useful for treating asthma or allergy.

11. The invention as hereinbefore described.

Claims

1. A pharmaceutical formulation comprising:
1 to 200 mg/mL of an antibody;
1 to 100 mM of a buffer;
0.001 to 1% of a surfactant;
10 to 500 mM of a stabilizer, wherein the stabilizer is a sugar selected from sucrose and trehalose;
at a pH in the range of from 4.0 to 7.0,
wherein the antibody is an antibody against P-selectin.

2. The formulation according to claim 1 which is a liquid formulation or a lyophilized formulation or a liquid formulation reconstituted from a lyophilized formulation.

3. The formulation according to claims 1 or2, wherein the antibody concentration is in the range of 10 mg/mL to 150 mg/ml.

4. The formulation according to claims 1 or 2, wherein the stabilizer is trehalose.

5. The formulation according to claims 1 or 2 wherein the surfactant is polysorbate.

6. The formulation according to claims 1 or 2 wherein the buffer is a histidine-buffer.

7. The formulation according to claims 1 or 2, which comprises a tonicity agent.

8. The formulation according to claims 1 or 2, wherein the tonicity agent is trehalose.

9. The formulation of claim 1 which comprises:
1 to 50 mg/mL huMAb-P-selectin, 20 mM L-histidine HCl, 240 mM trehalose, 0.02% polysorbate 20, at pH 6.0;
or
1 to 50 mg/mL huMAb-P-selectin, 20 mM sodium acetate, 140 mM trehalose, 75 mM glycine, 0.04% polysorbate 20, at pH 5.2;
or
1 to 50 mg/mL huMAb-P-selectin, 20 mM L-histidine HCl, 240 mM trehalose, 0.02% polysorbate 20, at pH 6.0;
or

1 to 50 mg/mL huMAb-P-selectin, 20 mM succinate, 240 mM trehalose, 20 mM arginine, 0.02% polysorbate 20, at pH 6.0.

10. Use of a formulation according to any one of claims 1 to 20 for the preparation of a medicament useful for treating asthma or allergy.